Chardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $1.25 price target on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 70.77% from the stock’s current price.

Several other equities research analysts also recently commented on MCRB. The Goldman Sachs Group cut their price objective on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a report on Friday, March 14th. StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Seres Therapeutics Price Performance

NASDAQ:MCRB traded down $0.05 during trading hours on Thursday, reaching $0.73. 998,438 shares of the stock were exchanged, compared to its average volume of 3,414,403. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $1.53. The firm has a 50 day moving average of $0.79 and a 200 day moving average of $0.83. The stock has a market cap of $127.45 million, a PE ratio of -3.18 and a beta of 2.19.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Avantax Advisory Services Inc. lifted its holdings in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC lifted its holdings in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares during the last quarter. Virtu Financial LLC lifted its holdings in Seres Therapeutics by 44.8% during the 3rd quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC increased its position in Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares during the period. Finally, Northern Trust Corp increased its position in Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after buying an additional 44,461 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.